Scarica l'app Stockscreener
10.41
5.28%
-0.58
Dopo l'orario di chiusura:
10.46
0.05
+0.48%
Precedente Chiudi:
$10.99
Aprire:
$10.85
Volume 24 ore:
34,970
Relative Volume:
0.28
Capitalizzazione di mercato:
$154.15M
Reddito:
$54,000
Utile/perdita netta:
$-210.26M
Rapporto P/E:
-13.18
EPS:
-0.79
Flusso di cassa netto:
$-159.01M
1 W Prestazione:
+9.35%
1M Prestazione:
+8.61%
6M Prestazione:
-13.97%
1 anno Prestazione:
-67.67%
Intervallo 1D:
$10.26
$11.16
Intervallo di 1 settimana:
$9.24
$11.16
Portata 52W:
$7.65
$34.90
Lyell Immunopharma Inc Stock (LYEL) Company Profile
Nome
Lyell Immunopharma Inc
Settore
Industria
Telefono
650 695-0677
Indirizzo
201 HASKINS WAY, SOUTH SAN FRANCISCO
Confronta LYEL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LYEL
Lyell Immunopharma Inc
|
10.41 | 162.74M | 54,000 | -210.26M | -159.01M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-30 | Downgrade | BofA Securities | Buy → Underperform |
| 2024-06-27 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-08-28 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-11-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-11 | Downgrade | Goldman | Buy → Neutral |
| 2022-10-17 | Iniziato | H.C. Wainwright | Buy |
| 2021-07-12 | Iniziato | BofA Securities | Buy |
| 2021-07-12 | Iniziato | Goldman | Buy |
| 2021-07-12 | Iniziato | JP Morgan | Overweight |
| 2021-07-12 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Lyell Immunopharma Inc Borsa (LYEL) Ultime notizie
What makes Lyell Immunopharma Inc. stock attractive to long term investorsFree Stock Movement Tracking - jammulinksnews.com
What analysts say about Lyell Immunopharma Inc. stockLightning-fast capital gains - jammulinksnews.com
What drives Lyell Immunopharma Inc. stock priceFastest return on investment - Autocar Professional
Positive week for Lyell Immunopharma, Inc. (NASDAQ:LYEL) institutional investors who lost 70% over the past year - simplywall.st
Lyell Immunopharma Inc. Stock Analysis and ForecastHigh-yield investments - jammulinksnews.com
Is Lyell Immunopharma Inc. a good long term investmentFree Predictions - jammulinksnews.com
Lyell Immunopharma's LYL314: A High-Risk, High-Reward Catalyst in the CAR T-Cell Space - AInvest
Lyell: 'Hold' Rating Based On Phase 3 LYL314 LBCL Treatment Program Advancement (LYEL) - Seeking Alpha
Lyell Immunopharma registers 625,000 shares for resale - MSN
why lyell immunopharma inc. stock attracts strong analyst attentionStable Stocks With High Yield - Newser
Lyell Immunopharma (NASDAQ:LYEL) Stock Price Down 5.9% – What’s Next? - Defense World
Why Lyell Immunopharma Inc. stock attracts strong analyst attentionShort Term High Return Strategy - Newser
What makes Lyell Immunopharma Inc. stock price move sharplyPredictable High Return Trades - Newser
How Lyell Immunopharma Inc. stock performs during market volatilityFree Stock Market Trend Analysis - Newser
Lyell Immunopharma’s (LYEL) “Neutral” Rating Reiterated at HC Wainwright - Defense World
Lyell Immunopharma (NASDAQ:LYEL) Trading 3.5% Higher – What’s Next? - Defense World
Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series - GlobeNewswire
Lyell reports new clinical data from trial of large B-cell lymphoma therapy - Yahoo Finance
Lyell’s lymphoma therapy shows high response rate in trial - Investing.com
Lyell’s lymphoma therapy shows high response rate in trial By Investing.com - Investing.com Nigeria
Lyell Immunopharma Announces Promising CAR T-Cell Trial Data - TipRanks
Lyell Immunopharma Says LYL314 Shows 'Robust' Responses in Large B-Cell Lymphoma Trial - marketscreener.com
Lyell Immunopharma (LYEL) Releases Promising Results from LYL314 Trial | LYEL Stock News - GuruFocus
Lyell Immunopharma Announces Positive Clinical Data From Phase 1/2 Trial Of Lyl314 For The Treatment Of Aggressive Large B-Cell Lymphoma - MarketScreener
Lyell Immunopharma Announces Positive New Clinical Data - GlobeNewswire
Lyell Immunopharma Stock Soars 23.11% Post Reverse Split - AInvest
Lyell Immunopharma (LYEL) Strengthens Leadership Team with Key A - GuruFocus
Lyell Immunopharma (LYEL) Announces Key Executive Appointments | LYEL Stock News - GuruFocus
Lyell Immunopharma Inc Azioni (LYEL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.32%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):